Novo Nordisk has just released the results of the phase 3 STEP-HFpEF trial showing that semaglutide was able to reduce symptoms and improve exercise capacity in overweight people with heart ...
Semaglutide and Atrial Fibrillation A subanalysis of data from the STEP-HFpEF and STEP-HFpEF DM trials 5 showed that patients with aFib—45% of the STEP-HFpEF program population—have ...
STEP-HFpEF, and STEP-HFpEF DM trials. According to the analysis, semaglutide led to a 31% reduced risk of combined cardiovascular (CV) death or worsening heart failure (HF) events, based on an ...
Results that may be inaccessible to you are currently showing.